AMP releases statement on diagnostics in drug labels
May 16, 2011 in MedicationsToday, the Association for Molecular Pathology (AMP) released its new position statement on the appropriate manner to reference diagnostic tests in drug labels. The association also met with officials from the United States Food and Drug Administration that participate in the effort to draft guidance documents for co-developed products and companion diagnostics to inform them of its new position statement.
With advances in genomic medicine, providers can use targeted therapy to tailor dosing, improve drug response, and to avoid adverse events. Pharmaceutical manufacturers control the label's content and can choose to describe a laboratory test by its molecular description or by its brand name. The latter limits pathologists from choosing the test that best suits the needs of their patients, physicians and laboratory environment. And rather than consulting with the molecular pathologist to consider all relevant information from the patient's medical history, together with the most effective laboratory testing strategy at the least cost, treating physicians such as oncologists may reflexively order the test listed in the labeling. Therefore, referencing diagnostic tests by their brand names in drug labeling may create a situation where patients are not receiving optimal care.
"When the FDA approves a label that includes a brand name of a diagnostic kit, the medical community often views this as a tacit endorsement of that one company's test," explained AMP Professional Relations Committee Chair Dr. Elaine Lyon, "Indeed, diagnostic companies' marketing strategies might exploit this view."
Because healthcare providers may request testing using the test identified in the drug labeling, and payers may only reimburse if that specific test is used, laboratories will be put in the challenging position of having to purchase and verify multiple test kits for the same analyte. In addition, if a diagnostic company was to sell its test exclusively to one laboratory, all specimens would have to be shipped to that laboratory for testing even if the source laboratory has access to a different FDA approved or cleared test for the same analyte. Dr. Lyon expressed AMP's concern, "this would drastically increase healthcare costs and over-complicate the laboratory environment. And our greatest concern is that it could result in restricting the patient's access to one specific test, which may create additional burdens to the patient including the collection of subsequent samples, increased out-of-pocket costs, and delayed treatment."
AMP hopes that this new position statement will encourage pharmaceutical companies to reference diagnostic tests based on its molecular description and the FDA to work with industry to reinforce the appropriate labeling of its products.
AMP's specific recommendations include:
- To promote patient safety and high quality care, AMP recommends that FDA specify that diagnostics be described by the biological description of the gene or mutation in drug labeling and that identification of recommended diagnostic testing not be by brand name. Essential performance characteristics (e.g. limit of detection) can be specified. Standardized HUGO nomenclature should be used.
- AMP notes that The Clinical Laboratory Standards Institute (CLSI) avoids identifying products by brand name in their Guidelines.
- Identification of diagnostic tests by brand name in drug labeling is only appropriate in the description of relevant clinical studies; AMP recommends that in the remainder of the label, pharmaceutical manufacturers reference the biological description.
More information: http://www.amp.org/
Provided by Association for Molecular Pathology
-
FDA approves new respiratory virus test
Jan 21, 2008 |
not rated yet |
0
-
FDA approves warfarin labeling change
Aug 16, 2007 |
not rated yet |
0
-
Mobile animal diagnostic lab is developed
Feb 24, 2006 |
not rated yet |
0
-
CDC seeks bird flu diagnostic tests
Dec 05, 2006 |
not rated yet |
0
-
Consumers call for more government oversight of commercial genetic tests
Jul 07, 2008 |
not rated yet |
0
-
Limits to growth: Scientists identify key metastasis-enabling enzyme
7 hours ago |
5 / 5 (1) |
0
-
Seeing is as seeing does: Spatially-structured retinal input in early development of cortical maps
Apr 26, 2012 |
5 / 5 (4) |
1
-
Dreamless nights: Brain activity during nonrapid eye movement sleep
Apr 09, 2012 |
4.4 / 5 (12) |
0
-
Take your time: Neurobiology sheds light on the superiority of spaced vs. massed learning
Mar 28, 2012 |
4.5 / 5 (21) |
3
-
Your brain on 'shrooms: fMRI elucidates neural correlates of psilocybin psychedelic state
Feb 29, 2012 |
4.9 / 5 (42) |
45
-
Math and dyslexia?
17 hours ago
-
portable metabolism meter?
May 21, 2012
-
Rare medical conditions on 20/20 tonight
May 18, 2012
-
"Good" Cholesterol in Doubt
May 17, 2012
-
A couple of questions about schizophrenia
May 17, 2012
-
Paralyzed woman uses thoughts to move robotic arm
May 17, 2012
- More from Physics Forums - Medical Sciences
More news stories
Antidepressant use associated with increased mortality among critically ill patients?
Researchers at Beth Israel Deaconess Medical Center, in Boston, and the Massachusetts Institute of Technology in Cambridge, have found that critically ill patients were more likely to die if they were taking the most commonly ...
Medications
6 hours ago |
not rated yet |
0
Antibiotics boost risk of infection with antifungal-resistant candida
Previous exposure to certain antibiotics could boost the risk of infection with drug-resistant strains of a severe fungal infection. Researchers report their findings in the May 2012 issue of the journal Antimicrobial Ag ...
Medications
7 hours ago |
not rated yet |
0
New blood thinner may lower chances of clots in high-risk heart patients: FDA
(HealthDay) -- The new blood thinner Xarelto appears to lower the chances of potentially fatal blood clots in high-risk heart patients, a U.S. Food and Drug Administration review has found.
Medications
18 hours ago |
not rated yet |
0
Generic versions of plavix approved
(HealthDay) -- The first generic versions of Plavix (clopidogrel bisulfate) have been approved by the U.S. Food and Drug Administration.
Medications
May 18, 2012 |
not rated yet |
0
'Last resort' antibiotics increasingly used to fight multidrug-resistant bugs
Multidrug-resistant pathogens are becoming more frequent, and the few "last resort" treatments available for infections with these bacteria have also shown an increase in use in recent years, according to a study published ...
Medications
May 16, 2012 |
not rated yet |
0
Scientists unravel role of fusion gene in prostate cancer
Up to half of all prostate cancer cells have a chromosomal rearrangement that results in a new "fusion" gene and formation of its unique protein -- but no one has known how that alteration promotes cancer growth. Now, Weill ...
Early-life risk factors for non-Hodgkin lymphoma
Factors influencing early life non-Hodgkin lymphoma (NHL) incidence include family characteristics, high fetal growth, older maternal age, low birth order, and male gender, according to a study published May 22 in the Journal of ...
Studies examine CPAP treatment and cardiovascular outcomes in adults with obstructive sleep apnea
Two studies that included adults with obstructive sleep apnea examined the effectiveness of reducing the risk of cardiovascular outcomes, including high blood pressure, by treatment with continuous positive airway pressure ...
Systems treating severe heart attacks expanding nationwide
The number of systems of care that quickly transfer and treat heart attack patients has increased substantially across the nation, according to research published in Circulation: Cardiovascular Quality and Outcomes, an American ...
Use of multicomponent intervention linked with decrease in using physical restraint in nursing homes
Nursing homes that used a multicomponent intervention that included staff training and supportive materials for staff, residents and relatives had a lower rate of use of physical restraints such as bilateral bed rails and ...
Limits to growth: Scientists identify key metastasis-enabling enzyme
(Medical Xpress) -- On the complex road to eradicating cancer, controlling or preventing metastatic growth initiated by primary tumors is high on the to-do list. A key area of such research is the development ...